Biotricity Q1 FY2027: Revenue Climbs 10%, Yet Going Concern and Series C Exchange Loom

summarizeSummary

Biotricity grew revenue 10% to $4.3M and generated positive operating cash flow, but a $31.7M working capital deficit, going concern warning, and a major Series C Preferred Stock exchange that could hand insiders 59.6% control keep the stock highly speculative.

check_boxKey Events · Earnings and Guidance · BTCY

• Series C Exchange Restructures Ownership

  Issued 2,009,197 Series C Preferred shares in exchange for 14.1M common shares, 4.0M options, and 1.4M warrants. Series C automatically converts to 59.6% of common shares upon a $15M qualified financing, or ten common shares per Series C share by March 31, 2028.

• Working Capital Deficit Nearly Doubles

  Working capital deficiency widened to $31.7M from $16.7M a year ago, driven by $14.8M current term loan and $11.0M convertible notes and short-term loans.

• Going Concern Warning Persists

  Auditors and management continue to flag substantial doubt about the company's ability to continue as a going concern, with only $466,503 in cash at quarter end.

• Revenue Grows, Cash Flow Turns Positive

  Revenue rose 10.4% to $4.28M, gross margin improved to 82.6%, and operating cash flow was $507K positive, but net loss attributable to common stockholders widened to $1.07M.

auto_awesomeAnalysis · BTCY · Industrial Applications And Services

Biotricity's Q1 FY2027 shows revenue growth and positive operating cash flow, but the company remains in a precarious financial position. The Series C Preferred Stock exchange gives insiders and investors a path to 59.6% ownership upon a $15M financing, while the working capital deficit has nearly doubled to $31.7M. The going concern warning persists, and the pending 1-for-100 reverse split adds further uncertainty.